RxSight Inc.‘s leadership unlawfully failed to accurately disclose the company’s financial situation and product adoption challenges, an investor alleged in a derivative complaint filed Monday at a California federal court.
The lawsuit comes less than a month after another investor filed a proposed class action against RxSight arising from the same issues. There, plaintiff Rumen Makaveev alleged the company concealed material information before it lowered its 2025 revenue forecast and endured record stock drops.
LeeAnne Swift says in her complaint that RxSight’s directors and officers omitted mention of the issues it faced between November 2024 and July with regards ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.